Genentech, a member of the Roche Group, has broken ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon. This expansion advances plans that were announced in August to increase capacity for advanced drug delivery devices. Also, the facility alongside others, will strengthen the company’s United States manufacturing capabilities.
Size and Timeline
The event marks the start of construction for the 211,000-square-feet expansion. This will foresee the doubling the size of the existing site. Commercial operations are planned to begin in 2031.
Furthermore, upon completion, the expanded facility will add device fill-finish capabilities. This will include the manufacturing of combination products, to Genentech’s U.S. manufacturing network.
Genentech’s Hillsboro Site to Manufacture Medicines Across Oncology, Neurology and Immunology
Additionally, with flexible high- and low-volume filling capabilities, the site is designed to manufacture a broad range of medicines across oncology, neurology and immunology. This added capacity will help strengthen Genentech’s domestic supply chain and support reliable access to medicines for patients.
Job Creation
The expansion will generate approximately 250 high-wage manufacturing jobs. Over the coming years, Genentech will recruit for specialized roles across several roles. These roles include filling and inspection, device assembly and packaging, cold storage, and quality control. Moreover, these roles will pair traditional manufacturing expertise with digital skills in AI, automation and robotics, creating a modern workforce equipped to drive innovation in precision manufacturing. Construction of the facility will also support approximately 200 additional construction jobs.
When was Genentech’s Hillsboro Campus Established?
Genentech established its Hillsboro campus in 2006. Today, the 75-acre campus is an important part of the company’s manufacturing network. It boasts capabilities spanning drug product manufacturing, packaging, distribution and individualized therapies.
Also, the decision to expand in Hillsboro reflects Genentech’s continued confidence in the area’s experienced workforce, established infrastructure and manufacturing expertise. Furthermore, it shows the company’s longstanding partnership with the Hillsboro community and the state of Oregon.
Roche and Genentech Investment in the US
The expansion is part of Roche and Genentech’s investment commitment in U.S. manufacturing and R&D. Additionally, it builds on recent manufacturing and investment milestones in Holly Springs, North Carolina and Boston, Massachusetts. Together, these investments expand an end-to-end U.S. footprint spanning research, development and manufacturing and reflect the companies’ long-term commitment to American scientific innovation. Roche and Genentech have approximately 25,000 employees in the U.S., with 15 R&D centers and 13 manufacturing sites.
Project Fact Sheet: Genentech Hillsboro Expansion
Project Name: Genentech Hillsboro Technical Operations (HTO) Facility Expansion
Company / Parent: Genentech, a member of the Roche Group
Location: Hillsboro, Oregon (75-acre campus)
Capital Investment: $750 Million
Milestone Event: Official Groundbreaking (Construction Phase Started)
Facility Specifications and Scope
Expansion Size: 211,000 square feet (doubling the footprint of the existing site)
Target Operational Date: 2031 (Commercial Operations Start)
Key Capabilities: Advanced drug delivery device fill-finish, combination products manufacturing, flexible high- and low-volume filling
Therapeutic Areas Served: Oncology, Neurology, and Immunology
Advanced Technology Integration: AI, automation, robotics, and digital twin technology for real-time monitoring
Economic and Workforce Impact
Manufacturing Roles Created: 250 high-wage specialized positions
Target Skillsets: Device assembly, drug filling/inspection, cold storage, quality control, AI, and digital manufacturing expertise
Construction Impact: 200 temporary construction jobs
Total Regional Job Creation: 450 total jobs
Corporate and Supply Chain Context
Primary Objective: Strengthen U.S. domestic supply chain for drug-delivery devices and combination therapies
Campus History: Established in 2006; handles drug product manufacturing, packaging, distribution, and individualized therapies
Broader U.S. Footprint (Roche/Genentech): 25,000 U.S. employees across 15 R&D centers and 13 manufacturing sites
Related Network Investments: Complementary facilities in Holly Springs, North Carolina and Boston, Massachusetts
Leave a Reply